<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1518">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01943500</url>
  </required_header>
  <id_info>
    <org_study_id>T30-0001</org_study_id>
    <nct_id>NCT01943500</nct_id>
  </id_info>
  <brief_title>Collection of Blood Specimens for Circulating Tumor Cell Analysis</brief_title>
  <official_title>Collection of Blood Specimens for Circulating Tumor Cell Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viatar LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commonwealth Hematology-Oncology, P.C.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Viatar LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To test the sensitivity of a proprietary novel filtration device designed to
      capture and concentrate circulating tumor cells (CTCs).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.</measure>
    <time_frame>Analysis will be performed within 96 hours following blood sample collection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples will be collected from study subjects and analyzed for the number of circulating tumor cells (CTCs) within 96 hours of blood collection.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer or no prior history of cancer</arm_group_label>
    <description>Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Confirmed patients with stage II-IV breast, prostate, or colorectal cancer, (Or) subjects
        with no prior history of cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of age

          -  Written informed consent obtained

          -  Confirmed diagnosis of stage 2-4 breast, prostate, or colorectal cancer, (OR) no
             prior history of cancer

          -  Stage 2-4 treatment naive, metastatic, secondary, and recurrent cancer patients

          -  Able to undergo blood collection prior to initiation of chemotherapy treatment, (OR)
             able to provide blood sample if subject is a non-cancer control subject

        Exclusion Criteria:

          -  Patients unable to understand the research protocol and/or provide informed consent.

          -  Patients with known immunodeficiency, or pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro M Sanz-Altamira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Commonwealth Hematology-Oncology, P.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Commonwealth Hematology-Oncology, P.C.</name>
      <address>
        <city>Lawrence</city>
        <state>Massachusetts</state>
        <zip>01841-2310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro M Sanz-Altamira, MD, PhD</last_name>
      <phone>978-946-8230</phone>
      <email>psanz@chomed.com</email>
    </contact>
    <investigator>
      <last_name>Pedro M Sanz-Altamira, MD, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 21, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Circulating tumor cell (CTC)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
